Colorado BioScience Association announces eight 鶹ѰBoulder companies will present at 2026 Rocky Mountain Life Sciences Investor & Partnering Conference
Colorado BioScience Association (CBSA)—Colorado BioScience Association (CBSA) has announced the presenting companies selected for the 2026 Rocky Mountain Life Sciences Investor & Partnering Conference Presented by BioMed Realty, bringing a powerful cross-section of high-growth life sciences opportunities to investors and strategic partners in Vail, Sept. 30-Oct. 2, 2026. The lineup features close to 50 companies from Colorado and the Rocky Mountain West, including eight from 鶹ѰBoulder.
The conference highlights investment-ready companies and creates opportunities to build relationships that help companies grow, scale and succeed.
鶹ѰBoulder Companies
Funding Sought: $3M Seed
Illumen Therapeutics, is pursuing a novel therapeutic strategy to treat aggressive cancers, such as colorectal and pancreatic cancers, by restoring functional p53 through inhibiting the enzyme PARN. This breakthrough in oncology drug development avoids the historical problems exhibited with MDM2 inhibitors. Read About Their 鶹ѰConnection
Funding Sought: $4M Seed
Renovare Therapeutics is a biotechnology company developinga pipeline of regenerative therapies for osteoarthritis (OA), a disease impacting 500 million patients globally with no disease-modifying treatments available. Their technology spans advanced particle drug delivery, regenerative biomaterials and engineeredgene therapy, allowing us to addressthe full disease spectrum. Read About Their 鶹ѰConnection
Think Bioscienceis a privately held small molecule drug discovery company based in Boulder, Colorado, focused on developing therapeutics against targets that have historically been considered “undruggable”. The company’s team combines expertise in synthetic biology, protein biophysics, applied enzymology, computational chemistry and medicinal chemistry to launch a first-in-class program for diseases with high unmet need. Read About Their 鶹ѰConnection
VitriVax is a Boulder, Colorado-based biotechnology company advancing the ALTA® (Atomic Layering Thermostable Antigen and Adjuvant) platform, a novel technology designed to overcome key challenges in vaccine delivery. ALTA® combines thermostabilization and controlled-release technologies to protect vaccine components from degradation and enable programmable antigen release over time. The platform has the potential to eliminate cold-chain requirements, reduce multi-dose vaccination schedules to a single administration and support the co-formulation of multiple vaccine components in a single product. Read About Their 鶹ѰConnection
Flari
Flari is building a breath analysis platform based on cutting-edge quantum sensing technologies that represent a new category of analytical methods for studying molecular biology and metabolomics. This platform can support research and development as well as test development and implementation. It promises to broaden testing options for a wide variety of diseases and monitoring needs. Read About Their 鶹ѰConnection
Funding Sought: $5M Seed
TissueForm has developed Allovia™, a flowable implant for repairing cartilage defects that provides immediate structural support. Made from natural materials derived from human cartilage tissue, Allovia is an off-the-shelf, resorbable implant designed to support the body’s natural healing response in the knee. Read About Their 鶹ѰConnection
Funding Sought: $2.75M Seed
Transformative Biotech is transforming PCR testing for infectious diseases with patented direct-to-PCR platform technologies. Clinically validated on more than 590,000 patient samples, our platform enables rapid, accurate and affordable molecular testing. @ANYWHERE™, our smartphone-powered handheld PCR platform in development, is designed to expand access to testing, accelerate treatment and reduce the spread of infectious diseases worldwide, ultimately saving lives.
Funding Sought: $5M Seed
VitaWave Tech is developing eBP, a clinical-grade, in-ear blood pressure monitor that delivers FDA AAMI-compliant accuracy with the ease of an earbud. Targeting hypertension, preeclampsia and chronic kidney disease patients, eBP enables remote patient monitoring through a connected mobile app and provider portal with EHR integration. Read About Their 鶹ѰConnection
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,senior marketing and communications specialist for Venture Partners at 鶹ѰBoulder.
For media inquiries, please visit .